New Standard of Care? Abraxane Wins Nod in Pancreatic Cancer
The FDA approved Celgene Corp.’s Abraxane Friday for use in pancreatic adenocarcinoma. It’s the first drug approved for patients with metastatic pancreatic cancer in nearly eight years, and analysts are expecting the combination of the albumin-bound version of paclitaxel and gemcitabine to become the new standard of care in what has remained an intractable disease.
Outside of the US
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST